Use of Glasgow Benefit Inventory (GBI) in Meniere's disease managed with intratympanic dexamethasone perfusion: Quality of life assessment

作者：Kyrodimos Efthimios; Aidonis Ioannis; Skalimis Anargyros^*; Sismanis Aristides

来源：Auris Nasus Larynx, 2011, 38(2): 172-177.

DOI：10.1016/j.anl.2010.07.009

• Intratympanic dexamethasone perfusion
• Meniere's disease
• Glasgow Benefit Inventory
• Quality of life

Objective: To evaluate patients' quality of life following intratympanic dexamethasone perfusion in management of Meniere's disease (MD).
Methods: This is a retrospective study in a tertiary referral center that uses the Glasgow Benefit Inventory (GBI). Intratympanic perfusion of 24 mg/ml of dexamethasone was administered after failure to respond to previous management with diuretics and low-salt diet. GBI questionnaires were collected and analyzed in a 12 months follow-up of participating patients.
Results: Thirty patients (20 women and 10 men, aged 28-85 years) with MD underwent intratympanic dexamethasone perfusion and were assessed with the assistance of GBI questionnaire. Follow-up ranged from 12 to 48 months (mean 30 months). Audiometric results were also available in all of them. In the short term (4 weeks post-perfusion) 6 patients demonstrated a greater than 10 dB improvement in PTA, and 6 patients had an increase in SDS of at least 15%, while in the long-term (12 months post-perfusion) the number of patients in the respective groups decreased to 5 and 2. With regards to the GBI responses, 9 patients (50%) expressed an overall benefit, while 6 (33%) expressed no benefit and 3 patients (17%) complained of negative effect after the intervention.
Conclusion: The mean GBI score indicates substantial improvement in patients' overall quality of life following intratympanic dexamethasone perfusion, which was also confirmed by the audiometric results.

• 出版日期2011-4